The global neurological biomarkers market is poised for significant growth, driven by the increasing demand for accurate diagnosis and treatment monitoring of neurological disorders. According to a recent market analysis, the sector is projected to witness a robust Compound Annual Growth Rate (CAGR) of 4.6% over the forecast period, reaching an estimated US$ 12.5 billion by 2033. In 2023, the market was valued at US$ 8 billion, highlighting a notable upward trajectory.
Neurological biomarkers play a critical role in the diagnosis and monitoring of various neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. These advancements in precision medicine are propelling the growth of the neurological biomarkers market. The increasing demand for enhanced diagnostic tools and effective treatment monitoring solutions is further fueling the sector’s expansion.
Fetch Your Sample Report Encompassing The Latest Market Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-6626
Key drivers of the neurological biomarkers market:
- Rising prevalence of neurological disorders
- Growing demand for accurate and early diagnosis
- Increasing adoption of personalized medicine
- Technological advancements in biomarker discovery and development
This press release highlights the significant potential of the neurological biomarkers market and its anticipated growth trajectory. As the demand for accurate diagnosis and effective treatment of neurological disorders continues to rise, the market is expected to witness further advancements and innovation in the coming years.
Key Takeaways:
- During the forecast period, the US is expected to account for a significant share of the global neurological biomarkers market. This is attributed to the best scientists and industry-leading laboratories who drive the development of more advanced biomarker tactics, as well as specialized testing and on-target protocol help, to accelerate clinical biomarkers projects.
- The neurological biomarkers market in the Asia-Pacific is predicted to hold the largest share, particularly in Japan and India, during the projected period. This is owing to the launch of novel solutions such as PET scanners with motion correction, as well as the development of methods that enable significantly earlier sickness diagnosis, improved prognoses, and increased treatment options in order to increase the lifetime of future generations.
- Owing to expanding research and development initiatives towards the production of personalized medications for neurological illnesses, the “genomic biomarkers” type is expected to hold the highest revenue through the forecast period.
- As it is the most common of all neurological disorders, the “Alzheimer’s disease” application type accounts for a significant share and is the most profitable area for manufacturers.
Discover The Power Of Methodology-Driven Insights: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-6626
Competitive Landscape:
Industry players engage in numerous planned product launches and global expansion to promote the brand and sales. They are also expanding their presence across various geographies and entering new markets, especially in developing regions, to expand their customer base and strengthen their presence. The introduction of new innovative products in the market is also being carried out by market players, owing to the increasing number of neurological disorders across the world. These factors are anticipated to expand the global neurological biomarkers market size. The following companies are key leaders in the global market for neurological biomarkers:
- Quanterix
- Qiagen
- ADx NeuroSciences NV
- Merck KGaA
- Enrolmmun
- Thermo Fisher Scientific
- ACOBIOM
- Banyan Biomarkers Inc.
- Olink Biosciences
- Bio-Rad Laboratories Inc.
Recent Developments:
- In August 2020, Johnson & Johnson Services, Inc. entered into an agreement with Enigma Biomedical Group for the evaluation of novel neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to understand Alzheimer’s disease and other dementias.
- In 2019, MC10 Inc. announced the collaboration with the University of Rochester for the development of novel digital biomarkers for central nervous system diseases.
Key Segments Profiled in the Neurological Biomarkers Market Survey:
By Type:
- Genomics Biomarkers
- Proteomics Biomarkers
- Metabolomics Biomarkers
- Imaging Biomarkers
- Others
By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Schizophrenia
- Depression
- Multiple Sclerosis
- Spinal Muscular Atrophy
By End User:
- Research Organizations
- Pharma & Biotech Companies
- Clinical Diagnostics
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
- Europe
Act Now to Explore In-Depth Market Analysis: Purchase Now to Access Industry Insights: https://www.futuremarketinsights.com/checkout/6626
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube